Eli Lilly says experimental obesity drug combo shows stronger weight loss in trial
The drugmaker plans to begin Phase 3 trials combining its amylin drug eloralintide with tirzepatide by the end of the year after positive mid-stage results.
Written by EGazette’s AI. The facts are drawn from cited sources; the analysis is the AI’s own.
Eli Lilly said a combination treatment pairing its experimental amylin drug eloralintide with its existing obesity medication tirzepatide produced greater weight loss than either drug alone in a mid-stage clinical trial, according to CNBC.
The pharmaceutical company said it plans to advance the combination regimen into Phase 3 trials, the final stage of testing typically required before a drug can be submitted for regulatory approval. Lilly indicated those trials are expected to begin by the end of the year.
Building on tirzepatide's success
Tirzepatide, sold under the brand names Zepbound for weight loss and Mounjaro for diabetes, has already become one of Lilly's best-selling products amid surging global demand for GLP-1 and related weight-loss medications. Eloralintide targets a different biological pathway, working on the hormone amylin, which is involved in regulating appetite and blood sugar.
Combining drugs that act on different pathways has emerged as a key strategy among obesity drug developers, who are racing to produce treatments that deliver greater weight loss with fewer side effects than current options.
Lilly did not disclose detailed trial results, including the specific magnitude of weight loss achieved in the mid-stage study, in the portion of its announcement reported by CNBC.
The company's move to push the amylin-tirzepatide combination into late-stage testing signals confidence in the approach, though the drug would still need to clear Phase 3 trials and regulatory review before reaching patients. Lilly faces competition from rivals including Novo Nordisk, which is also developing next-generation obesity treatments as the weight-loss drug market continues to expand rapidly.
Analysts have closely watched Lilly's obesity drug pipeline given the scale of investment pouring into the category, with weight-loss medications increasingly viewed as one of the pharmaceutical industry's largest growth opportunities in years. A successful combination therapy could help Lilly extend its lead in the market as competition intensifies.
Sources
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial — CNBC — Top News
EGazette summarizes reporting from multiple sources; follow the links for the originals.
Comments
Loading comments…
Related articles
Lady A singer Charles Kelley reveals blood cancer diagnosis
The Grammy-winning country music star says he currently feels "great" and remains hopeful following his diagnosis.
Medicine prices soar in Iran as sanctions squeeze pharmaceutical supply
Patients and families are struggling to find some treatments as US sanctions pressure Iran's drug industry.
Patients switching from Wegovy injections to Novo's pill version kept losing weight, real-world study finds
Early real-world data suggest patients may not need weekly injections indefinitely to maintain weight loss on Wegovy.
HHS Report Claims Gender-Affirming Care 'May' Contribute to Radicalization, Drawing Criticism
Critics say the federal report frames transgender identity as illegitimate or dangerous, part of what they describe as an ongoing effort to undermine established care models.
Foster Care System Often Falls Short for Children With Disabilities, Data Shows
Disabled children make up the largest group in foster care and face the worst outcomes, including the longest stays and highest mortality risk, according to reporting on the system.
Former M5S Leader Di Battista in Treatment After Brain Tumour Surgery
Alessandro Di Battista fell ill during a visit to Cuba and has had most of a brain tumour removed, according to reports.